Latest Breaking News On - Efficacy outcomes - Page 1 : comparemela.com

Cassava Sciences Reports Q1 2024 Financial Results and Clinical Updates on Phase 3 Trials of Simufilam

Cassava Sciences Reports Q1 2024 Financial Results and Clinical Updates on Phase 3 Trials of Simufilam
wallstreet-online.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wallstreet-online.de Daily Mail and Mail on Sunday newspapers.

United statesPuerto ricoNew yorkSouth koreaEric schoenCassava sciences incResearch internationalCassava sciencesPremier research internationalBoth phaseMonitoring boardEfficacy outcomesExtension studyFirst quarterNew york cityCassava science

Eupraxia Pharmaceuticals Announces Upcoming Presentations at the Osteoarthritis Research Society International World Congress 2024

Eupraxia Pharmaceuticals Announces Upcoming Presentations at the Osteoarthritis Research Society International World Congress 2024
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

James helliwellWorld congressEupraxia pharmaceuticals incOsteoarthritis research society internationalEupraxia pharmaceuticalsEfficacy outcomesKnee osteoarthritisPer protocol analyses fromWeek studyLong acting intra articular injectionFluticasone propionateIntra articular injectionRegarding forward looking statementsAlthough eupraxia

Methylprednisolone as Adjunct to Endovascular Thrombectomy for Large-Vessel Occlusion Stroke

This clinical trial assesses the efficacy and adverse events of adjunctive intravenous low-dose methylprednisolone to endovascular thrombectomy for patients wit

Mei yangMin zhangDe yangUnited statesQian xiChang liuUnited kingdomLin jiangEteläuomen läiLos angelesNei mongolXiang liuZhouzhou pengYoulin wuQingwu yangGuoyong zeng

IASO Bio and Innovent Present New Data of FUCASO® (Equecabtagene Autoleucel) for Multiple Myeloma Patients in Oral Presentation at ASH 2023

IASO Bio and Innovent Present New Data of FUCASO® (Equecabtagene Autoleucel) for Multiple Myeloma Patients in Oral Presentation at ASH 2023
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesSan diegoEquecabtagene autoleucelJue wangChunrui liEli lillyInnovent biologicsAdimab incyteInnovent biologics incMd anderson cancer centerAmerican society of hematologyUnion medical collegeTongji medical collegeChina national medical products administrationInstitute of hematologyChinese academy of medical sciences

IASO Bio and Innovent Present New Data of FUCASO® (Equecabtagene Autoleucel) for Multiple Myeloma Patients in Oral Presentation at ASH 2023

/PRNewswire/ IASO biotechnology ("IASO Bio"), a biopharmaceutical company engaged in discovering, developing, manufacturing and marketing innovative cell.

United statesChunrui liJue wangInnovent biologicsEquecabtagene autoleucelAdimab incyteEli lillyInnovent biologics incUnion medical collegeChina national medical products administrationHuazhong university of science technologyAmerican society of hematologyMd anderson cancer centerTongji medical collegeChinese academy of medical sciencesInstitute of hematology